1 EXHIBIT 11.1 INCYTE PHARMACEUTICALS, INC. STATEMENT RE COMPUTATION OF LOSS PER SHARE (In thousands, except per share amounts) Three Months Ended March 31, -------------------- 1997 1996 ------ ------ Primary Earnings Per Share - -------------------------- Weighted average common shares outstanding during the period 10,455 10,034 Adjustment for dilutive effect of outstanding stock options 998 - ------ ------ Weighted average common and common equivalent shares used for primary earnings (loss) per share 11,453 10,034 ====== ====== Net income (loss) 981 (2,038) ====== ====== Net income (loss) per share $0.09 ($0.20) ====== ====== Fully Diluted Earnings Per Share - -------------------------------- Weighted average common shares outstanding during the period 10,455 10,034 Adjustment for dilutive effect of outstanding stock options 998 - ------ ------ Weighted average common and common equivalent shares used for fully diluted earnings (loss) per share 11,453 10,034 ====== ====== Net income (loss) 981 (2,038) ====== ====== Net income (loss) per share $0.09 ($0.20) ====== ======